GC Corp. (KRX:005250)
South Korea
· Delayed Price · Currency is KRW 14,210
+30 (0.21%)
At close: Apr 28, 2026
3.42% (1Y)
| Market Cap | 645.16B |
| Revenue (ttm) | 2.45T |
| Net Income (ttm) | -69.51B |
| Shares Out | 45.40M |
| EPS (ttm) | -1,531.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 300.00 (2.12%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 60,708 |
| Average Volume | 89,994 |
| Open | 14,180 |
| Previous Close | 14,180 |
| Day's Range | 14,100 - 14,320 |
| 52-Week Range | 13,240 - 17,700 |
| Beta | 0.62 |
| RSI | 51.09 |
| Earnings Date | Apr 3, 2026 |
About GC Corp.
GC Corp. operates as a biotechnology company. The company provides prescription drugs and over-the-counter drugs; aseptic fill and finish services for drug manufacturing; and pharmaceutical logistics services. It also researches and develops plasma derivatives for von Willebrand disease and primary immunodeficiency; vaccines for mRNA flu, anthrax, tetanus, diphtheria, pertussis, tuberculosis, and varicella; recombinant treatments for acquired thrombotic thrombocytopenic purpura, fabry, hemophilia, hunterase, colon cancer, and hunter syndrome; a... [Read more]
Industry Biotechnology
Sector Healthcare
Founded 1967
Employees 144
Stock Exchange Korea Stock Exchange
Ticker Symbol 005250
Financial Performance
Financial StatementsNews
MedGenome Makes a Majority Investment in Leading Gujarat-Based Diagnostics Chain Green Cross to Expand Genomics Offerings Across India
Business Wire India This partnership brings together the legacy of trusted diagnostics along with the combined network, infrastructure, science, technology,...
6 months ago - Business Upturn